Elucidating mechanisms of chemoresistance is critical to improve cancer therapy, especially for the treatment of pancreatic ductal adenocarcinoma (PDAC). Genome-wide association studies have suggested the little studied gene HEATR1 as a possible determinant of cellular sensitivity to different chemotherapeutic drugs. In this study, we assessed this hypothesized link in PDAC, where HEATR1 expression is downregulated significantly. HEATR1 silencing in PDAC cells increased resistance to gemcitabine and other chemotherapeutics, where this effect was associated with increased AKT kinase phosphorylation at the Thr308 regulatory site. Mechanistically, HEATR1 enhanced cell responsiveness to gemcitabine by acting as a scaffold to facilitate interactions between AKT and the protein phosphatase PP2A, thereby promoting Thr308 de-phosphorylation.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy. The prognosis of patients with PDAC is dismal with a five-year survival of less than 5%. Anti-tumor drugs and radiation therapy are current treatment options for PDAC, however drug resistance frequently occurs. Thus, understanding molecular mechanisms contributing to the resistance of PDAC to chemotherapy will provide clues for new targeted therapies.
Akt is a central module to regulate cell proliferation and survival, angiogenesis and glucose metabolism (1, 2) . Aberrant Akt activation is associated with diverse pathophysiological states including cancers and chemoresistance (3, 4) . Akt controls these cellular functions through phosphorylating substrates. Akt directly phosphorylates BAD, preventing it from inhibiting prosurvival Bcl-2 family members (5, 6) . Akt regulates glucose metabolism through phosphorylating and inactivating GSK3 (7) . In addition, Akt negatively regulates FOXO and p53 and blocks the transcription of BIM, Puma and Noxa (8, 9) . Furthermore, Akt promotes protein synthesis and cell growth through activation of mammalian target of rapamycin (10) .
Akt activity is tightly controlled at multiple levels. where Akt is phosphorylated at Thr308 (11) . Ubiquitination of Akt by TRAF6 and Skp2-SCF E3 ligase is required for the recruitment of Akt to plasma membrane (12, 13) . Full
Akt activity requires phosphorylation of both Thr308 and Ser473 mediated by phosphoinositide-dependent kinase 1 (PDK1) (14) and mammalian target of rapamycin (mTOR) complex 2 (mTORC2) (15) , respectively. On the other hand, protein phosphatase 2A (PP2A) (16) (17) (18) and PH domain leucine-rich repeat protein phosphatase (PHLPP) (19, 20) dephosphorylate AktThr308 and Ser473, respectively. FKBP51
promotes dephosphorylation of Akt Ser473 through acting as a scaffolding protein for
Akt and PHLPP (21) . However, how Akt is targeted to PP2A is not clear.
HEAT repeat-containing protein 1 (HEATR1) contains HEAT repeats, which was initially found in a diverse family of proteins including huntingtin, elongation factor-3 and the PR65/A subunit of protein phosphatase 2A (22) . Except for a couple of reports suggesting HEATR1 may regulate rRNA synthesis and cytotoxic T lymphocytes in patients with glioma (23, 24) , the cellular function of HEATR1 remains largely unknown.
Here, we report that HEATR1 regulates cancer cell response to multiple classes of chemotherapeutic drugs. Mechanistically, HEATR1 affects survival of pancreatic cancer cells to chemotherapy through affecting Akt activity. We demonstrate that HEATR1
functions as a scaffold protein to regulate Akt phosphorylation by PP2A. Furthermore, our study identifies HEATR1 as a potential prognostic marker of pancreatic cancers. 
Materials and Methods

Cell Culture and Plasmids
Human pancreatic cancer cell lines SU86.86, ASPC-1, and PANC-1 were purchased from ATCC in 2014 and the identities of all cell lines were confirmed by the medical genome facility at Mayo Clinic Center using short tandem repeat profiling upon receipt. The cell lines were maintained in RPMI 1640 with 10% FBS. HEATR1 cDNA was purchased from Thermo Scientific and full length and mutants were subcloned into pIRES-EGFP.
PP2A-Aα, B55α, B56β, Cα were purchased from addgene and subcloned into HA-pcmv and pGex4T-1. HEATR1 siRNA and shRNA were from Dharmacon and sigma, respectively.
MTS Assay
Gemcitabine was from Eli Lilly (Indianapolis, IN). Paclitaxel, SN-38, mitomycin c, oxaliplatin and etopside were from Sigma-Aldrich (St. Louis, MO). Triciribine was from EMD Biosciences (San Diego, CA). Ctrl or HEATR1 siRNA or shRNA were transfected, and the growth-inhibitory effect was performed as described previously (21) .
Tumor xenograft study
Female athymic nu/nu mice were obtained from the National Cancer Institute. 
Immunohistochemical Staining and image analysis
Tissue microarray was constructed following standard tissue array producing protocols as described previously (25) . Primary antibodies were both rabbit polyclonal antibody for HEATR1 and pAkt308, followed by incubation with the secondary antibody. Highsensitivity diaminobenzidine chromogenic substrate system was used for colorimetric visualization. The density of positive staining was measured by a computerized image system including Leica-CCD camera connected to a Leica-DM-IRE2 microscope. Under high-power magnification, photographs of representative fields were captured by the 
Results
HEATR Regulates pancreatic cancer cells response to chemotherapy
We have performed several genome wide association studies to identify genes whose expression associates with sensitivity to chemotherapy. Interestingly, we found that HEATR1 gene, although not among the top hits in these studies, associates with response to several drugs, including gemcitabine and 1-beta-d-arabinofuranosylcytosine (26) . We 
HEATR1 regulates Akt phosphorylation at Thr308 by promoting Akt-PP2AB56β interaction
Since HEATR1 affects cellular response to a broad range of chemotherapeutic agents, it is likely that HEATR1 affects a common pathway such as apoptosis. Gemcitabine induced apparently stronger apoptosis in control cells than in cells transfected with HEATR1 shRNA (Supplementary Fig.S2A ). Next, we investigated how HEATR1 affects chemotherapy response by probing several pathways regulating cell death. We found that downregulation of HEATR1 led to an increased phosphorylation of Akt at Thr308, but not at Ser473 (Figure 2A Since HEATR1 specifically regulates Thr308, it is likely that HEATR1 regulates signaling events that directly control Akt phosphorylation at Thr308. Thr308 of Akt is phosphorylated by PDK1 and dephosphorylated by PP2A (16, 18, 27) . No apparent difference of PDK1 phosphorylation was observed in control and HEATR1-depleted cells TCN-P, the active metabolite of Akt inhibitor triciribine (TCN), binds to PH domain of Akt and prevents its recruitment to cell membrane, where Akt is phosphorylated by PDK1 at Thr308 (28) . When TCN was used alone, no significant difference of cytotoxicity and apoptosis was observed in different cell lines transfected with control and HEATR1 siRNA ( Supplementary Fig.S4A-E) . In addition, TCN did not significantly affect gemcitabine sensitivity and apoptosis in control cells. However, TCN sensitized cells depleted of HEATR1 to gemcitabine ( Figure 4A-B, Supplementary Fig.S4B-E Figure 5A ). Furthermore, low HEATR1 proteins levels correlates with increased Akt phosphorylation at Thr308 in representative pancreatic cancer samples ( Figure 5B ). We next evaluated whether HEATR1 expression was associated with the response of patients to standardized gemcitabine chemotherapy. As shown in Figure 5C-D, Supplementary Fig.S5 and Supplementary Table 1, PDAC patients with high HEATR1 or low AktT308 expression in tumors had a significant improvement in overall survival. Thus, determination of HEATR1 expression in PDAC tissues may be useful as an independent predictor for gemcitabine response. Based on IOD value, we observed a negative correlation between HEATR1 expression and Akt phosphorylation at Thr308 in tumor tissues ( Figure 5E ). Meanwhile, we observed a significant correlation between the Akt308 phosphorylation and TNM staging, lymph node metastasis, whereas we did not find the correlation between HEATR1 expression and clinical pathological feature (Supplementary Table 2 ). From multivariate survival analysis, HEATR1 expression and Akt308 phosphorylation might be independent prognostic factors among these variables (Supplementary Table 3 ). Overall, our results showed that HEATR1 negatively regulates Akt activation and upregulation of Akt activity by loss of HEATR1 in pancreatic cancers might give rise to the resistance to chemotherapy ( Figure 6 ).
Discussion
Despite continuous efforts, effective early detection markers of PDAC are currently not available and approximately 80% of patients are diagnosed at locally advanced or metastatic stages (29) . In these patients at advanced stage, limited response to current Here we found that depletion of HEATR1 in pancreatic cancer cells causes resistance to gemcitabine and other chemotherapeutic agents (Figure 1 and Supplementary Fig.S1 ).We propose that HEATR1 functions in gemcitabine resistance through inhibiting Akt activity. The evidences we observed are as follows. First, the interaction between Akt and B56β was decreased when HEATR1 was depleted, indicating that HEATR1 acts as a scaffolding protein for Akt and B56β, theraby enhancing the phosphatase activity of B56β toward Thr308 (Figure 2) . Second, HEATR1 mutants that abolish Akt or B56β interaction failed to affect Akt Thr308 phosphorylation and chemosensitity ( Figure 3) .
Third, addition of triciribine (TCN) sensitizes gemcitabine treatment in cells with low HEATR1 level both in vitro ( Figure 4A ) and in animal models (Figure 3B-D) . Finally, we demonstrated that expression of HEATR1 is positively correlated with overall survival in patients with pancreatic cancer ( Figure 5 ).
Identification of diagnostic and prognostic biomarkers for PADC patients has attracted much attention (29) . However, existing biomarkers such as CA19-9 are not adequate as early detection markers of pancreatic cancer and predictor to treatment response because of low sensitivity and specificity (37) . The biological function of HEATR1 in sensitizing pancreatic cancer cell to gemcitabine is potentially important. We report here that thus making it difficult to restore HEATR1 expression in PADC cancer cells. In the future, after we are able to narrowdown small motifs of HEATR1 responsible Akt or PP2A binding, we might be able to engineer a polypeptide to restore the regulation of Akt by PP2A. In addition, if we are able to identify the mechanism of HEATR1 downregulation in PDAC, we might be able to restore HEATR1 expression. However, how the expression of HEATR1 is deregulated in PDAC is unclear. From public databases, we did not found that HEATR1 mRNA to be downregulated in PDAC (TCGA and Oncomine). The HEATR1 gene is mutated in a small percentage of pancreatic cancer cases (3.4% TCGA), however, this could not account for all pancreatic cancers showing weak IHC staining. We speculate that HEATR1 is downregulated in pancreatic cancer at posttranscriptional level. Possible mechanisms include decreased translation or protein turnover. Thus, further investigation is essential to understand how HEATR1 is dysregulated in cancers. As an alternative strategy, combination therapy using an Akt inhibitor and gemcitabine was able to overcome gemcitabine resistance in PDAC.
Our study provides evidence of HEATR1 as a potential biomarker for predicting chemoresistance, although clinic outcomes of the combination of therapies targeting Akt plus gemcitabine should be further tested. It would also be interesting to investigate whether HEATR1 is potentially implicated in cancer development considering the role of Akt in cancers. Furthermore, although our study mostly focused on gemcitabine and PDAC, our findings that HEATR1 affects the response to other chemotherapeutic agents would have broader impact for the treatment of other cancers and should be validated in CAN-15-0671 the future. In summary, we identify HEATR1 as a negative regulator of the Akt pathway in PADC and a potential biomarker for predicting chemo-resistance. 
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